Table 3.
Effects of combined renin angiotensin system and neprilysin inhibition on tracheal plasma extravasation in the rat.
| Compound | Tracheal plasma extravasation | APP inhibition Ki or IC50 (nmol/L) | References |
|---|---|---|---|
| ACE AND NEPRILYSIN INHIBITION | |||
| Ecadotril (99% neprilysin & 23% ACE inhibition) | No | No | (5, 107) |
| Lisinopril (83% ACE inhibition) | No | No | (10, 11, 107, 108) |
| Ecadotril & Lisinopril | Yes | No | (5, 107) |
| Omapatrilat (>90% ACE & 53% neprilysin inhibition) | Yes | 194, 250, 260 | (10, 11, 13) |
| ARB AND NEPRILYSIN INHIBITION | |||
| Valsartan (100 mg/kg) | No | No | (11) |
| Candoxatril (100 mg/kg) | No | No | (11) |
| Valsartan & candoxatril | No | No | (11) |
| Omapatrilat (0.3 mg/kg) | Yes* | 194, 250, 260 | (10, 11, 13) |
*
Plasma extravasation caused by omapatrilat was prevented by prior icatibant administration (11). ACE, angiotensin converting enzyme; APP, aminopeptidase P; ARB, type 1 angiotensin II receptor blocker.